Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Hematologic Neoplasms 1

Interventions

venetoclax 308Cyclophosphamide 231Cytarabine 201Azacitidine 191fludarabine 181Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 82Rituximab 79Daunorubicin 77Dexamethasone 76Vincristine 69Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 58Tacrolimus 55Etoposide 53ibrutinib 52blinatumomab 51Granulocyte Colony-Stimulating Factor 51obinutuzumab 50Busulfan 50Prednisone 49Melphalan 48acalabrutinib 47Injections 46Stem Cell Transplantation 45Idarubicin 45Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
poly(I).poly(c12,U) × Other hematologic neoplasm × 1 year × Clear all
NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Roswell Park Cancer Institute

Phase 1/2 Terminated
4 enrolled 30 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡